Shots:
- The US FDA has received the IND application for UTRxM1-18, a novel therapy targeting c-MYC-driven cancers, to initiate P-I trial in 2026 pending approval, focusing on c-MYC driven tumors incl. triple-negative breast, pancreatic, colorectal, & ovarian cancer
- UTRxM1-18 has demonstrated strong, dose-dependent efficacy against human-derived tumors from multiple cancer subtypes, with no dose-limiting toxicities in animal models
- UTRxM1-18 leverages UTR’s Ultra-Targeted RNA platform to selectively degrade oncogenic c-MYC motifs by switching the ribosome machinery from a translational to a degradation program in tumor cells, allowing precise tumor targeting with strong safety & tolerability in healthy cells
Ref: Globenewswire | Image: UTR Therapeutics
Related News:- ALK Reports Health Canada’s Approval of Itulatek to Treat Children and Adolescents with Allergic Rhinitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
